Skip to content

Microbial analysis of different types of chronic sinusitis patients and its impact on disease prognosis

Microbial analysis of different types of chronic sinusitis patients and its impact on disease prognosis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103368
Enrollment
Unknown
Registered
2025-05-28
Start date
2023-04-01
Completion date
Unknown
Last updated
2025-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic sinusitis

Interventions

Chronic sinusitis without nasal polyps group:None
Chronic sinusitis with nasal polyps group:None
Normal control group:None

Sponsors

Shanxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 150 patients with chronic sinusitis who underwent surgical treatment in our hospital were randomly selected as the study subjects, and 50 patients with non sinusitis related nasal surgery were selected as the normal control group. The diagnostic criteria for CRS are based on the guidelines of the European Position Paper on Rhinosinusitis and Nasal Polyps 2020(EPOS2020).

Exclusion criteria

Exclusion criteria: Patients with comorbidities such as cystic fibrosis, ciliary immobility syndrome, respiratory diseases exacerbated by aspirin, immunodeficiency, allergic fungal sinusitis, and inverted papilloma were excluded; No oral corticosteroids or antibiotics were taken within 4 weeks before surgery; All patients with combined intestinal diseases and those who have suffered from intestinal diseases within one month.

Design outcomes

Primary

MeasureTime frame
Gut Microbial flora;Gamma-interferon;Interleukin 4;Interleukin 5 ;Interleukin 13;Interleukin 17A;

Countries

China

Contacts

Public ContactWeihong Bai

Shanxi Provincial People's Hospital

wei05hong16@163.com+86 150 3419 6205

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026